Replimune Group (NASDAQ:REPL) Stock Price Expected to Rise, BMO Capital Markets Analyst Says

Replimune Group (NASDAQ:REPL) had its target price boosted by stock analysts at BMO Capital Markets from $18.00 to $27.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ price target points to a potential upside of 104.58% from the company’s previous close.

A number of other analysts have also recently weighed in on REPL. HC Wainwright increased their price target on Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday. Jefferies Financial Group increased their price target on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Finally, JPMorgan Chase & Co. raised their price objective on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $19.14.

Replimune Group Stock Up 11.4 %

Shares of NASDAQ:REPL traded up $1.35 during trading on Wednesday, hitting $13.20. The company’s stock had a trading volume of 584,264 shares, compared to its average volume of 833,930. The company has a market capitalization of $903.01 million, a PE ratio of -4.33 and a beta of 1.28. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The stock’s 50-day moving average price is $12.16 and its two-hundred day moving average price is $11.24.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. As a group, sell-side analysts expect that Replimune Group will post -2.91 EPS for the current year.

Insider Buying and Selling

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

Institutional investors have recently bought and sold shares of the stock. Point72 DIFC Ltd acquired a new stake in shares of Replimune Group in the second quarter valued at about $57,000. Erste Asset Management GmbH acquired a new stake in Replimune Group during the third quarter worth about $133,000. China Universal Asset Management Co. Ltd. grew its position in Replimune Group by 82.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after buying an additional 5,926 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Replimune Group by 81.7% during the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock valued at $165,000 after purchasing an additional 6,748 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in Replimune Group during the third quarter valued at approximately $222,000. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.